JAK inhibitor study for severe skin rash caused by immunotherapy
Part of Cancer, Immune system & allergy, Skin clinical trials.
This study tests a new pill (a JAK inhibitor) for people with severe skin rashes from cancer immunotherapy that did not improve with standard treatments. The goal is to see if the drug can safely ease the rash.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a solid tumor cancer and have been treated with an immunotherapy drug (like PD-1, PD-L1, or CTLA-4 inhibitors).
- You developed a severe (grade 3-4) skin rash from that immunotherapy.
- The rash did not go away with corticosteroids or other immune-suppressing medicines.
- Your blood cell counts and liver/kidney function meet certain minimum levels.
- You do not have active infections like HIV, hepatitis B or C, or shingles.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a JAK inhibitor pill for people with severe skin rashes caused by immunotherapy drugs like Keytruda or Opdivo. It aims to help control the rash and allow you to keep benefiting from your cancer treatment.
This study looks at how well JAK inhibitor pills work for children with alopecia areata (a condition that causes hair loss). If you have tried one of these medicines for at least 3 months, your experience could help doctors learn more about the best treatments.
This trial tests a combination of two medications—guselkumab and a JAK inhibitor—for people with inflammatory bowel disease that hasn't responded to other treatments. The goal is to see if this combination is safe and effective for patients with hard-to-control Crohn's disease or ulcerative colitis.
This trial tests a new pill called jaktinib for people who develop moderate to severe acute graft-versus-host disease (aGVHD) after a stem cell transplant. The goal is to see if adding jaktinib to standard steroid therapy can better control the disease.
This trial tests an oral medication called ICP-332 for adults with moderate to severe eczema (atopic dermatitis) who haven't gotten enough relief from topical creams. It aims to see if the drug can reduce skin inflammation and itching.
This study tests whether switching to a new oral medication (ivarmacitinib) helps people with moderate-to-severe eczema who still have symptoms even after using a standard injectable treatment (IL-4Rα inhibitor like dupilumab) for at least 12 weeks. It aims to see if the switch is effective and safe for these patients.
Hear when a new Immune Checkpoint Inhibitor-Induced Dermatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.